Association between statin use during hospitalisation and mortality in patients with intracerebral haemorrhage: a propensity score-matched cohort study

• Published in: BMJ open Vol. 12; no. 12; p. e065849
• Main Authors: Yuan, Min, Zhou, Xinhua, Lu, Xiaoqing, Xiao, Zhilong, Zhou, Huangyan, Wang, Xiaohua
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group LTD 30.12.2022; BMJ Publishing Group
• Series: Original research
• Subjects: Adolescent; Age; Aneurysms; Blood platelets; Cardiac arrhythmia; Cerebral Hemorrhage - drug therapy; Chlorine; Chronic obstructive pulmonary disease; Cohort analysis; Cohort Studies; Creatinine; Diabetes; Ethnicity; Glucose; Heart failure; Hemorrhage; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; Hypertension; Intensive care; Leukocytes; Mortality; Neurology; Nitrogen; Patients; Propensity Score; Retrospective Studies; Statins; United States > US; Massachusetts; stroke medicine; stroke; public health; pharmacology
• ISSN: 2044-6055; 2044-6055
• DOI: 10.1136/bmjopen-2022-065849

We examined the relationship between statin use during hospitalisation and mortality in patients with intracerebral haemorrhage (ICH). Retrospective propensity-matched cohort study. Patients with ICH (≥18 years old) admitted to Beth Israel Deaconess Medical Center (Boston, Massachusetts, USA) from 2001 to 2012 registered in the Medical Information Mart for Intensive Care III database. 1043 patients with ICH (≥18 years) were evaluated for the relationship between statin use during hospitalisation and mortality. Statin use. The primary outcome was 90-day mortality. We used multivariable Cox regression analyses to calculate the adjusted HR with 95% CI and used propensity score analysis and an inverse probability weighting (IPW) model to ensure the robustness of our findings. We included 1043 patients with ICH (362 and 681 were statins and non-statin users, respectively) between 2001 and 2012. The overall 90-day mortality was 29.8% (311/1043); it was 33.3% (227/681) and 23.2% (84/362) for non-statin and statin users, respectively. After adjusted for potential confounders, we found that statin use was associated with 29% lower of 90-day mortality (HR=0.71, 95% CI 0.52 to 0.97, p<0.05). IPW also demonstrated a significantly lower 90-day mortality in statin users. The HR was 0.69 (95% CI 0.54 to 0.88, p<0.01). The results remain stable in subgroup analyses and propensity score matching. Statin use during hospitalisation may be associated with reduced risk-adjusted mortality in patients with ICH. Further randomised controlled trials are needed to clarify this association.